Makers of Mesothelioma Drug May Seek FDA Fast-Track Approval

The company said clinical studies for the drug have shown some promise, leading researchers to proclaim at a recent meeting of the American Society of Clinical Oncology that Alimta, combined with a course of cisplatin, should be considered front-line therapy for those with mesothelioma.

The data, collected as part of the largest Phase III study ever to examine mesothelioma, was presented by Dr. Nicholas Vogelzang, director of …